Arkolith/Insider Trading/XLO/Form 4

Shannon James Samuel

DirectorXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Jun 18, 2025
Net Buying
Open-Market Buys
$48K
Open-Market Sells
$0
Net Open-Market Flow
$48K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 17, 2025Buy(P)25K$0.69$17K70K
Jun 16, 2025Buy(P)45K$0.69$31K45K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-017705) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML